Genes linked to development of glaucoma

Article

An international study led by King's College London has identified genetic links to glaucoma.

An international study led by King's College London has identified genetic links to glaucoma.

In a study published in Nature Genetics, researchers conducted a meta-analysis of more than 35,000 people from 7 countries, including subjects of Asian and European descent, with data drawn from the International Glaucoma Genetics Consortium (IGGC).

They found four new genes associated with high intraocular pressure and glaucoma. One of the genes is the ABO gene, which determines blood group, and higher eye pressure appears to be linked to blood group B.

The study also found that a genetic change in the ABCA1 gene is associated with an increased risk of developing both high inner eye pressure and glaucoma. ABCA1 is a major regulator of cellular cholesterol and lipid levels.

The researchers point out that, in the future, it may be possible to provide intensive screening to those identified as being at higher genetic risk.

Treatments could be targeted at reducing the amount of ABCA1 in the eye either by using chemicals to block the proteins produced by the gene or by altering the gene's expression.

To read the abstract of the study, click here.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.